Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00347971 · ClinicalTrials.gov registry record · Phase 1
Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by ZymoGenetics.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00347971 is a Phase 1 study that has completed, run by ZymoGenetics. The registered enrollment target is 23 participants.
The verdict
NCT00347971, a Phase 1 study, has completed, sponsored by ZymoGenetics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate whether recombinant IL-21 used in combination with rituximab is safe for patients with non-Hodgkin's lymphoma (NHL).
Interventions
- DRUG recombinant human interleukin 21 and rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00347971
The ClinicalTrials.gov registry entry for NCT00347971 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZymoGenetics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which recombinant human interleukin 21 and rituximab is the first listed.
NCT00347971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00347971 about?
NCT00347971 is a clinical study titled "Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma". The purpose of the study is to evaluate whether recombinant IL-21 used in combination with rituximab is safe for patients with non-Hodgkin's lymphoma (NHL).
What is the current status of trial NCT00347971?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2006-06. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00347971?
The interventions under investigation include: recombinant human interleukin 21 and rituximab (DRUG).
Who is sponsoring clinical trial NCT00347971?
This trial is sponsored by ZymoGenetics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.